Genetic Interruption of PD-1/PD-L1 as an Alternative Means for Immune Checkpoint Blockade in Cancer: A Review

Генетическое прерывание оси PD-1/PD-L1 как альтернативный способ блокирования иммунных контрольных точек при раке: обзор
Songwei Tan, Dan Li, Jiao Lu, Qianru Li, Huan Deng
2026-06-18

CAR-T cell engineeringCRISPR/Cas9PD-1/PD-L1 axisRNA interferencegenome editing
Background/Objectives: Immune checkpoints are critical regulatory pathways that maintain peripheral tolerance and prevent autoimmunity. Among these, the programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) axis serves as a major inhibitory pathway that terminates T cell responses. While protein-based checkpoint blockade (ICB) targeting this axis has revolutionized clinical cancer therapy, its clinical efficacy is frequently limited by low response rates, immune-related adverse events (irAEs), and the emergence of adaptive resistance. To break through these bottlenecks, genetic interruption has emerged as a high-precision alternative to modulate the PD-1/PD-L1 pathway at the nucleotide level. Methods: A comprehensive systematic review of literature was performed across major databases (PubMed, Web of Science), with a focus on high quality studies published up to 2026. Results: Direct genomic disruption via CRISPR/Cas9 and post-transcriptional silencing through RNA interference can effectively neutralize inhibitory signaling at its source. Recent advances demonstrate that targeting upstream regulatory nodes—including metabolic checkpoints (e.g., lactate metabolism) and biophysical mechanisms (e.g., liquid–liquid phase separation)—provides superior transcriptional control over PD-L1. Furthermore, engineering CAR-T cells with multiplex gene editing (e.g., TCR/B2M/PD-1 knockout) or localized scFv secretion significantly enhances antitumor potency while reducing systemic toxicity. Innovations in organ-targeted lipid nanoparticles and stimuli-responsive biomimetic carriers further address the delivery barriers in solid tumors. Conclusions: Gene therapy provides a high-precision platform for PD-1/PD-L1 modulation, offering a viable strategy to overcome adaptive resistance. Future clinical application depends on the refinement of safer editing tools, such as base editing, and the standardization of intelligent delivery systems to ensure controllable and scalable cancer immunotherapy.
1
CRISPR/Cas9-mediated genomic disruption and RNA interference can neutralize PD-1/PD-L1 inhibitory signaling directly at the genetic or post-transcriptional level.
2
Genetic interruption offers a high-precision alternative to protein-based PD-1/PD-L1 checkpoint blockade, potentially addressing low response rates, immune-related adverse events, and adaptive resistance.
3
Multiplex-edited CAR-T cells, including TCR/B2M/PD-1 knockouts, and localized scFv secretion can enhance antitumor activity while reducing systemic toxicity.
4
Organ-targeted lipid nanoparticles and stimuli-responsive biomimetic carriers address delivery barriers in solid tumors, while safer editing tools and standardized delivery systems remain necessary for clinical translation.
5
Targeting upstream regulators, including lactate metabolism and liquid–liquid phase separation, may provide stronger transcriptional control of PD-L1 than direct pathway targeting.

The PD-1/PD-L1 immune checkpoint pathway in cancer, including tumor cells and engineered immune cells

Genetic interruption and modulation of PD-1/PD-L1 signaling to improve antitumor efficacy, overcome adaptive resistance, and reduce systemic toxicity

Publication Details
Publication Date
2026-06-18
Journal
Publisher
ISSN
Cited by
2
Access Type
Author Information
Authors
Songwei Tan
Dan Li
Jiao Lu
Qianru Li
Huan Deng
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%